Evogene Q1 2024 GAAP EPS $(0.08) Beats $(0.09) Estimate, Sales $4.190M Beat $3.500M Estimate
Portfolio Pulse from Benzinga Newsdesk
Evogene reported its Q1 2024 financial results, with a GAAP EPS of $(0.08) beating the estimate of $(0.09) and sales of $4.190M surpassing the $3.500M estimate.
May 23, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evogene's Q1 2024 financial results exceeded expectations with a GAAP EPS of $(0.08) beating the $(0.09) estimate and sales of $4.190M surpassing the $3.500M estimate.
Evogene's better-than-expected earnings and revenue figures are likely to positively impact its stock price in the short term. Beating both EPS and sales estimates typically boosts investor confidence and can lead to a stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100